Why do SOC 2 and HIPAA create different access governance requirements?

Why the governance requirements diverge

SOC 2 and HIPAA both affect access governance, but they do so from different directions. SOC 2 is an assurance model that asks whether controls are suitably designed and operating as described. HIPAA is a legal and regulatory regime for protected health information, so access decisions must also satisfy healthcare-specific accountability, minimum-necessary use, and disclosure expectations.

That difference changes what “good” looks like. Under SOC 2, a control can be acceptable if it is well defined, consistently evidenced, and aligned to the service commitment. Under HIPAA, the same control may still be insufficient if it does not support role-based access, traceability, or the ability to explain who accessed PHI, why they accessed it, and whether that access was permitted for the purpose.

For practitioners, the key point is that governance is not just about whether access exists, but whether the access model can survive scrutiny under the stricter obligation in play. A single entitlement process may serve both regimes, but the HIPAA side usually demands more explicit restriction, documentation, and review discipline than a SOC 2 readiness program alone.

How scope and evidence shape the access model

The scope difference is often the first place the gap appears. SOC 2 is tied to the controls a service organisation chooses to operate and evidence to support trust services criteria. HIPAA is tied to PHI handling, which means access governance must follow the data, the workforce or vendor role, and the permissible use or disclosure context around the information itself.

That is why a SOC 2 control can be operationally sound yet still too generic for healthcare. For example, a periodic access review may show that reviewers signed off on who had access, but HIPAA may still require a stronger account of whether those users needed the access to perform a covered function, whether shared access was avoided, and whether exceptions were tracked tightly enough to justify PHI exposure.

In practice, this is where access review evidence becomes more than a checkbox. Healthcare environments often need to show not just that reviews happened, but that the review criteria were PHI-aware and the response to overexposure was timely. Healthcare Identity Security Guide is useful here because it frames how shared workstations, clinician access, and third parties change the access-governance problem.

Why one access rule may satisfy assurance but fail healthcare governance

SOC 2 tends to tolerate a broader range of implementation choices so long as the organisation can prove consistency, risk treatment, and evidence of operation. HIPAA is less forgiving when the access model cannot support healthcare accountability, especially where PHI, business associates, or operational exceptions are involved. The result is that the same access rule may be “auditable” in one context and “under-scoped” in the other.

That distinction shows up in role design, recertification depth, and exception handling. A role that is broad but stable may be fine for an assurance narrative if it is monitored and justified. For HIPAA, the same role may need tighter segmentation, explicit purpose limitation, and clearer owner accountability because access to PHI carries a disclosure obligation, not just an internal control objective. IAM and IGA Basics helps explain why the authorization model matters as much as the review cadence.

That is also why lifecycle discipline matters. If joiners, movers, and leavers are not handled cleanly, SOC 2 may record an internal control weakness, but HIPAA can turn the same weakness into a privacy and disclosure problem. Joiner-Mover-Leaver (JML) Guide is a good fit for this difference because healthcare access governance depends on timely removal of stale access and accurate role changes.

Risk and Threat Considerations

When access governance is designed only for assurance evidence, organisations can end up with controls that look complete on paper but do not meaningfully reduce PHI exposure. The main risk is over-trusting generic review or logging processes that do not distinguish healthcare sensitivity, vendor access, shared clinical workflows, or the disclosure consequences of overbroad entitlement.

Failure mechanism: Broad roles, stale access, weak exception handling, or shallow recertification can leave users with more PHI access than their current duties justify, and the issue may persist because the control still produces acceptable audit evidence.

Impact: The organisation may pass a SOC 2 control test yet still expose itself to HIPAA enforcement, privacy incidents, or unnecessary PHI disclosure if it cannot demonstrate access limitation and accountability at the point of use.

Practitioner Guidance

What to verify: Test whether the access model can answer three questions cleanly for PHI-bearing systems: who had access, why they needed it, and how promptly access changed when roles changed. If any one of those answers depends on manual explanation instead of control evidence, the model is too weak for HIPAA even if it is adequate for SOC 2.

Decision rule: Treat SOC 2 evidence as a baseline control signal, not as proof of healthcare compliance. If a role, exception, or shared-access pattern would be hard to defend to a privacy or compliance reviewer, narrow it before you rely on the control for PHI systems.

Practitioner takeaway: The governance bar is set by the stricter obligation in scope, so design access controls once but validate them against the most demanding accountability requirement they must satisfy.

Related resources from NHI Mgmt Group

• When do NHI access reviews create more value than a one-time cleanup?
• When does JIT access create more risk than it reduces?
• What is the difference between role-based access and API key governance for NHI security?
• Why do autonomous agents create different governance requirements from classic ML workloads?